Behrenbruch Christian 4

What Happened

• Christian Behrenbruch, MD & Group CEO and Director of Telix Pharmaceuticals (TLX), acquired a total of 67,935 ordinary shares in two open-market purchases on April 28–29, 2026.
• Transactions: 34,500 shares at an average A$14.48 (A$499,560) on Apr 28; 33,435 shares at an average A$14.87 (A$497,178) on Apr 29. Total consideration reported: A$996,738. These were purchases (a cash buy, commonly viewed as a positive/accumulative action rather than a sale).

Key Details

• Transaction dates and reported prices:
  • 2026-04-28: 34,500 shares at reported avg A$14.48 (footnote F1: actual trades ranged A$14.42–A$14.58).
  • 2026-04-29: 33,435 shares at reported avg A$14.87 (footnote F4: actual trades ranged A$14.54–A$14.72).
• Currency: Purchase prices reported in Australian Dollars (A$) (footnote F2).
• Ownership after transaction: Not specified in the provided filing excerpt.
• Related party note: Footnote F3 states Dr. Behrenbruch is the sole director and shareholder of Elk River Holdings Pty Ltd (disclosure of related entity).
• Timeliness: The Form 4 was filed on 2026-05-06 for transactions on 2026-04-28/29 — the filing was late (reported several days after the trades).

Context

• These were straightforward open-market purchases (transaction code P). Purchases by a CEO can be of interest to retail investors as an indication of the insider acquiring shares, but filings don’t explain motivation.
• Footnotes indicate the reported column prices are averages and the filer offers to provide a full breakdown of the per-trade prices within the stated ranges on request.